FDA approves first drug for rare genetic brain disorder
The U.S. Food and Drug Administration has approved the first treatment for type 3 Gaucher disease, a rare inherited condition that damages the brain and nervous system. According to FOX 35 Orlando and KTVU, the drug Infilbray (venglustat) was approved for patients weighing at least 15 kilograms, or about 33 pounds.
Type 3 Gaucher disease occurs when the body cannot break down fatty substances properly because of a deficient or malfunctioning enzyme. These substances build up in organs, tissues, and the brain over time, causing serious health problems. Unlike type 1 Gaucher disease, type 3 affects the brain and nervous system, leading to difficulties with balance, coordination, speech, memory, and thinking that can worsen progressively and significantly impact quality of life.
Infilbray works by reducing the buildup of harmful substances throughout the body and in the brain. According to the FDA, the drug can cross the blood-brain barrier, meaning it can reach the source of the buildup causing neurological symptoms. The FDA said the approval brings a new treatment option for patients with this rare disease and their healthcare providers.
Sources
- ktvu.com: US approves first drug for rare genetic neurological disorder
- FOX 35 Orlando: US approves first drug for rare genetic neurological disorder
